Sign In
Last checked at 
20 Jun 2011 07:00
For immediate release | 20 June 2011 |
Futura Medical plc
("Futura" or "the Company")
CSD500 CE mark certification
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce it has been informed that the relevant Notified Body is satisfied that all outstanding points in the regulatory dossier for CSD500 have been resolved and has been recommended to their Review Panel for approval. The Panel'sapproval process typically takes a month and is already underway. A further statement will be made in the coming weeks regarding the issueof the CE mark certificate.
The CE mark certificate will enable CSD500 to be marketed and sold within 29 European territories and a number of other non-European territories that recognise the CE mark process. Reckitt Benckiser plc, makers of the Durex® branded condom have exclusive global rights to CSD500.
For any further information please contact:
Futura Medical plc |
|
James Barder, Chief Executive | Tel: +44 (0) 1483 685 670 |
|
|
mail to: james.barder@futuramedical.com | www.futuramedical.com |
|
|
Nomura Code Securities Limited |
|
Phil Walker / Giles Balleny | Tel:+44 (0)20 7776 1200 |
|
|
For media enquiries please contact: |
|
|
|
Buchanan Communications |
|
Mark Court / Jessica Fontaine | Tel: +44 (0) 20 7466 5000 |
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Follow the stocks
